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1. Introduction
There are several main reasons to begin a follow-up schedule after surgical treatment of the
primary cutaneous lesion in patients affected by melanoma.
The main goal is the early detection of disease recurrence, even if the impact of a prompt
treatment on prognosis is still debated (Barth et al 1995, Atkins et al 2008, Garbe et al 2008).
Several authors believe that early detection of asymptomatic metastases does not affect overall
survival (Barth et al 1995, Atkins et al 2008). Others (Garbe et al 2008) showed a clear survival
benefit for an early with respect to late metastases detection, with a 3-year survival rate of 76%,
compared to the 38% of patients with late diagnosis. The early relapse recognition might lead
to a more complete and less invasive surgical treatment, with potential benefits for the patient.
A loco-regional or distant spreading is a not uncommon event that arises in a percentage of
patients varying from 15 to 35%. Indeed, in melanoma patients the risk of spreading is strictly
related to the disease stage at diagnosis, and an effective follow-up program should taken in
account both the AJCC classification (Balch et al 2009; Piris, Mihm & Duncan 2011) (Table 1)
and the different patterns of metastatic dissemination related to site of primary, gender and
age of patients (Quaglino et al 2007). On the basis of recently updated AJCC classification
(Balch et al 2009), for patients affected by localized stage I or II melanomas, tumour thickness,
mitotic rate and ulceration are considered the most relevant prognostic parameters; ulceration
and thickness of primary tumour maintain a role as predictive independent factors on survival
also in stage III patients, together to the number of involved lymph nodes, whereas for patients
with distant metastases, elevated values of serum lactate dehydrogenase (LDH) define a
category with poor prognosis. According to the primary location, no difference in the relapse
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rate was found for melanomas located on the head-neck, back, anterior trunk, upper limb and
thigh-leg; conversely, a primary melanoma located to the foot was associated to a statistically
significant higher relapse rate with respect to all the other sites (Quaglino et al 2007). As regard
the first site of metastatic spreading, patients with a lower limb primary melanoma showed
more frequently loco-regional metastases, whereas distant spreading was mainly observed in
patients with melanoma located in the trunk (Savoia et al 2009). More in details, lower limb
location showed a low incidence of visceral metastases as first site of relapse, irrespectively of
the AJCC stage, compared to all other body sites (Quaglino et al 2007).
Clinical Staging Pathological Staging
0 Tis N0 M0 0 Tis N0 M0
IA T1a N0 M0 IA T1a N0 M0
IB T1b N0 M0 IB T1b N0 M0
T2a N0 M0 T2a N0 M0
IIA T2b N0 M0 IIA T2b N0 M0
T3a N0 M0 T3a N0 M0
IIB T3b N0 M0 IIB T3b N0 M0
T4a N0 M0 T4a N0 M0
IIC T4b N0 M0 IIC T4b N0 M0
III any T N 1-3 M0 IIIA T1-T4a N1a/2a M0
IIIB T1-T4b N1a/2a M0
T1-T4a N1b/2b M0
T1-T4a/b N2c M0
IIIC T1-T4b N1b/2b/2c M0
any T N3 M0
IV any T any N M 1 IV any T any N M 1
Table 1. Clinical and pathological staging, AJCC 2009.
The majority of guidelines encourage frequent clinical and radiological examination during
the first 5 years from the diagnosis, due to the fact that almost 90% of all metastases occur
during this period (Dummer et al 2011). However, it has been demonstrated that the time
course of first relapse depend to the AJCC stage: the progressive decrease of relapse trend and
the subsequent plateau is reached earlier in stage IA (after the second year) and later in stage
IIB/IIC (from 5th to 8th year); moreover, distant relapses as first site of recurrences showed a
low (<1.5%), but constant annual incidence, even beyond 10 years from diagnosis (Quaglino
et al 2007); these data support the opinion of several authors who believe that a lifelong
surveillance should be recommended (Garbe et al 2008, Dummer et al 2011).
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The second reason to include melanoma patients in a follow-up program is the early identifi‐
cation of possible further primary melanomas or other skin tumours. Development of more
than one primary melanoma in a sole patient is in fact a relatively common and well-recognized
phenomenon; its frequency varies from 1.2 to 8.2% in the most recent published series (Savoia
et al 2012) and it is probably due to a specific genetic background. In the majority of cases
recently described (Bower et al 2010; Doubrowsky & Menzies 2003), there is a significant
reduction in mean Breslow’s thickness from the first to the second and successive primary
melanomas, with a consequent favourable impact on prognosis. This is mainly resulting from
well-timed diagnosis during follow-up programs.
Some melanoma patients also have an increased risk to develop non-melanoma skin tumours.
In particular, 35% of patients affected by lentigo maligna melanomas develops others cutane‐
ous malignancies within 5 years from the first diagnosis (Farshad et al 2002); this is probably
related to the fact that this melanoma type prefers elderly patients with a chronic actinic skin
damage. Also the relatively good prognosis of these patients may play a role.
Finally, a follow-up schedule should also perform an educational role, with the purpose of
having a favourable impact on the population health and quality of life (Dummer et al 2010).
Melanoma patients should be instructed not only in regular self-examination of the skin but
also to avoid sunburns and prolonged unprotected solar or artificial ultraviolet exposure.
Patients must also be aware that family members have an increased melanoma risk, consequent
to both skin phototype and genetic background.
To date, even if these basic principles are approved, there is not a complete international
agreement about the better follow-up schedule, with several differences in timing and duration
between different Countries.
1.1. Imaging studies
Imaging studies can play a central role in the early detection of melanoma progression,
allowing to a better treatment for patients. However, it is not generally accepted that the an
early recognition of asymptomatic metastatic disease can affect the overall survival (Atkins et
al 2008, Bichakjian et al 2011) and many imaging studies are considered uneconomical and not
entirely risk-less for the patient. Thus, many international guidelines accept an imaging
surveillance only in patients considered at higher risk of recurrence, as well stage IIIB and
above, not approving the execution of instrumental tests in asymptomatic low risk patients
(Marsden et al 2010, Bichakjian et al 2011). However, while ultrasonography is not harmful,
relatively cheap and easy to perform, and can routinely be used not only in advanced, but also
in stage I-II patients. In particular, even if sonography is operator-dependent, it remains more
sensitive than clinical examination alone in the early identification of nodal metastases;
sensitivity of ultrasound can be further improved by fine needle aspiration cytology, reaching
the 80% in some selected series (Voit et al 2006, Negrier et al 2005). Higher sensitivity can be
achieved only by sentinel node mapping. On the contrary, ultrasonography is relatively
ineffective in detecting distant metastases: the calculated sensitivity for abdominal ultraso‐
nography was only 53%, in comparison with 85% for CT scan (Forschner et al 2010). Similarly,
traditional chest X-ray is less sensitive than CT-scan in the detection of lung metastases
(Negrier et al 2005).
After Surgery: Follow-Up Guidelines of Melanoma Patients
http://dx.doi.org/10.5772/55335
363
As a consequence of the high metabolic rate of melanoma cells, PET-CT can be useful to detect
metastases in stage IIC or stage III patients, as well as in disease monitoring in stage IV patients
(Bastiaannet et al 2009). This technique has a high sensitivity and allows an accurate study of
the whole body, except the brain. The value of PET-CT in the follow-up of melanoma patients
is supported by the recommendations from the update Swiss guidelines (Dummer et al 2011),
that encourage the use of PET-CTC every 6-12 months for the first 5 years from diagnosis in
stage IIC or stage III patients and by the fact that Swiss health insurances cover this imaging
technique. However, PET-CT is not effective in the detection of positive sentinel lymph nodes
in patients with primary melanomas (Negrier et al 2005, Clark et al 2006, Maubec et al 2007,
Marsden et al 2011).
1.2. Screening blood tests
Routinely laboratory investigations have a relatively limited role in melanoma follow-up
programs and are usually not recommended in asymptomatic patients affected by localized
cutaneous melanoma of any thickness (Marsed et al 2010, Negrier et al 2005, Bichakjian et al
2011). However, recent advances in molecular biology techniques have permitted, in last years,
the identification of several molecules with a potential prognostic and diagnostic role.
Melanoma patients with advanced disease share elevated lactate dehydrogenase (LDH) serum
levels. Nevertheless, this marker act as an unfavourable prognostic factor only in stage IV
disease and high LDH levels are also demonstrated in unspecific tissue necrosis conditions,
such as haemolysis or myocardial infarction. So, the role of LDH in detection and monitoring
of metastatic disease is still controversial (Wang et al 2004). As we mentioned in the previous
paragraphs, in the updated AJCC classification (Balch et al 2009), for patients with distant
metastases the presence of elevated lactate dehydrogenase serum levels define the M category,
characterized by a poor prognosis.
Tyrosinase is the key enzyme responsible for the first two steps of melanin biosynthesis and
is considered one of the most specific markers in melanocytic differentiation, as its expression
is limited only to cells of neural crest derivation, such as melanocytes, melanoma cells and
Schwann cells. Tyrosinase detection by reverse transcription-polymerase chain reaction (RT-
PCR) analysis was initially applied to the detection of melanoma cells in SLN (Li et al 2000).
More recently, the detection of tyrosinase transcripts using the nested RT-PCR has been
proposed to identify the presence of melanoma cells in the peripheral blood in patients who
have undergone radical surgery (Osella et al 2000), as well as a potential additional tool for
the identification of melanoma cells in bone marrow and biological fluids other than blood
(Gossein et al 1996, Hoon et al 1997, Osella et al 2003). However, the real diagnostic and
prognostic relevance of this test is still controversial and its role in clinical practice is not yet
fully defined.
The S-100 calcium binding protein represent an high-sensitive marker for melanocytic lesions,
even if is no specific, since it stain either melanocytes or Langerhans and Schwann cells. In
several studies it has been demonstrated to correlate with the tumour invasiveness in mela‐
noma patients. Even if literature data about the melanoma–associated antigen S-100 are still
controversial, the majority of published studies report that the percentage of patients with high
S-100 levels increase progressively from stage I-II (0-12%) up to stage IV (Schultz et al 1998,
Kaskel et al 1999, Jury et al 2000). The sensitivity and specificity of this marker in the identifi‐
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cation of patients with a metastatic spread seems to be higher when compared with tyrosinase;
the 64% of patients with serum S-100 levels exceeding 0.2mg/L showed distant metastases,
confirmed by FDG-PET/CT scan (Forschner et al 2010). S-100 could play a role also in diagnosis
of lymph node involvement: nodal metastases were identified in 19% of patients with high
serum S-100 levels (Forschner et al 2010). Actually, S-100 is considered a good marker for
melanoma relapse, especially for disease free stage III patients (Beyler et al 2006; Kruijff et al
2010), whereas in advanced stage patients, S-100 levels are related with treatment response
and disease relapse (Garbe & Leiter 2003). The updated Swiss guidelines for the treatment and
follow-up of cutaneous melanoma (Dummer et al 2011) suggest to monitorate S-100 levels
every 6-12 months for the first 5 years from melanoma diagnosis in all stage II and III patients;
for stage IV patients, timing of sampling for S-100 detection should be individualized for single
patients.
Elevated serum levels of cytokines (IL-6, -8 and -10), soluble IL-2 receptor and soluble adhesion
molecule (sICAM and sVCAM) (Eton et al 1998) has also been proposed as progression markers
in melanoma patients; however, the relatively low sensibility and specificity of these mole‐
cules, together with their low cost-effectiveness ratio make them little used in clinical practice.
To date, others melanoma-associated antigens, such as melanoma inhibitory activity (MIA)
and neuron-specific enolase (NSE) or molecular markers, including MART-1/Melan-A, gp100,
TRP-1 and -2 showed a lower sensitivity and specificity and literature data regarding their
potential role in the early detection of metastatic disease are still controversial. A multimarkers
analysis appears to be associated with a sensitivity increase in the detection of circulating
melanoma cells, but the impact of these data on patient’s survival has not yet been conclusively
defined.
2. Follow-up schedules according melanoma stage
2.1. In situ melanoma
Patients with a surgically treated in situ melanoma have no risk of metastases; so, the follow-
up program should not include radiological examinations. It is also debated if clinical follow-
up visits are needed. The 2010 UK guidelines of the British Association of Dermatologists
recommend only a return visit after the complete excision to explain diagnosis and the
education of patients to the self-examination for a new primary melanoma (Marseden et al
2010). Others authors recommend a closer follow up with a clinical check of the whole skin
every 6-12 months (Dummer et al 2011). Even if the majority of multiple primary melanomas
were identified within 1 year from the first diagnosis, a relevant percentage developed after 5
or also 10 year from the primary excision (Savoia et al 2012; van der Leest et al 2012), especially
in younger patients. Consequently, in our opinion in consideration of the favourable prognosis
of patients with a previous in situ melanoma, follow-up visits should be continuated, with the
purpose of early diagnosis of possible further primary melanomas. Patients should also be
instructed in avoidance of sunburn and informed that their consanguineous have an increased
melanoma risk.
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2.2. Stage IA melanoma
The 5-year overall survival of stage IA patients is over 90%, with virtually no risk of recurrences
for patients with melanomas < 0.5 mm and a slightly worse prognosis for those with non-
ulcerated 0.5-1 mm thick primary tumour (Einwachter-Thompson & MacKie 2008).
Considering this relatively low risk of disease progression, the revised UK guidelines for the
management of melanoma (Marsden et al 2010) not recommended routinely imaging staging,
due to the low true-positive rate and the high false-positive rate. According to the UK
guidelines, patients should underwent to a series of two to four visits over the first years from
the primary excision, in order to teach self-examination and then discharged from a regular
follow-up. Similarly, the National French federation of cancer centres and the French society
of dermatology suggest only periodical clinical examinations for patients in this clinical stage
(Negrier et al 2005). Clinical follow-up at 6 monthly intervals, with the possible additional use
of of ultrasonography, is considered appropriate by the majority of others groups (Quaglino
et al 2007; Garbe et al 2010). Moreover, abdominal ultrasound imaging and chest x-ray are
performed by many physicians to have baseline images for the further follow-up (Forschner
et al 2010).
Routinely serological tests are not generally recommended in melanomas in the initial stage;
however, the Catalan guidelines (Mangas et al 2010) suggest to perform at diagnosis complete
blood count and biochemistry (including alkaline phosphatase, gamma-glutamyltransferase
and lactate dehydrogenase) together with detection of molecular markers such as S-100, MIA
and tyrosinase in all patients excepted those affected by melanoma in situ. Standard blood
workup and LDH measurement should be repeated 6-monthly for the first 2 years and annualy
for the following 2 years (Mangas et al 2010).
2.3. Stage IB and IIA melanoma
In this group of patients the risk of recurrence is of 15-35%, mainly within the first 5 years from
diagnosis. A follow-up examination every 3 months at least for the first 5-years is recom‐
mended from the European consensus-based interdisciplinary guidelines (Garbe et al 2010),
in order to detect early any loco-regional recurrences; a similar schedule is proposed also by
Italian groups (Quaglino et al 2007). UK guidelines (Marsden et al 2010) admit checks every 3
months only for the first 3 years; then, patients should be instructed to self-examination also
for loco regional metastases and visited only once every 6 months to 5 years. No routine
instrumental investigations are required for this group of patients according UK follow-up
schedule. Several studies demonstrated that ultrasonography of in-transit routes and regional
lymph nodes are more sensitive than physical examination (89.2% vs. 71.4%) in the detection
of nodal metastases in patients with an intermediate melanoma thickness (Blum et al 2000,
Garbe et al 2003, Quaglino et al 2007). So, patients with a tumour thickness of 1 mm or more
should be asked to undergo lymph node ultrasound imaging every 6 months (Forschner et al
2010). Ultrasonography of regional lymph node every 3-6 months within the first 5 years from
diagnosis is suggested only for stage II patients also by French guidelines (Negrier et al 2005),
whereas others imaging procedures are considered as optional. The clinical experience of
major Italian referral centres for melanoma suggests performing a CT scan annually for the
first 5 years also in stage IIA.
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Screening blood tests are suggested only by Catalan guidelines, that propose standard blood
workup and LDH detection 2 times a year for the first 5 years and then annually for the
following 2 (Mangas et al 2010).
2.4. Stage IIB and IIC melanoma
UK guideline (Marsden et al 2010) did not recommend routine investigations also for stage IIB
and IIC patients, despite the higher risk of recurrences (40-70%, above all in years 2-4); only
self-examination and clinical visits 3-monthly for 3 years and 6-monthly to 5 years are
suggested.
For stage IIC patients, as well for the more advanced stages, both Italian (Quaglino et al 2007)
and French guidelines recommended not only a regional ultrasonography two times a year,
but also brain, chest and abdomen CT scan that should be carried out annually for the first 5
years (Negrier et al 2005). Also for this group of patients, screening blood tests almost 2 times
a years are recommended by Catalan authors (Mangas et al 2010).
Table 2 and 3 compare different follow-up visit schedules from European and US guidelines.
Clinical examination schedule (years 1-5 from diagnosis)
Stage* Dummer, 2011 Marsden, 2010 Mangas, 2010 Garbe, 2009 Quaglino, 2008 Négrier, 2005
In situ f-u visit every6-12 months
no f-u visit
required
f-u visit every 12
months
no f-u visit
required
f-u visit every 12
months NA
IA visit every6 months
visit every 3-4
months, then
discharged
visit every
3/6 months†
visit every
6 months
visit every
6 months
visit every
6 months
IB visit every3 months
visit every
3 months**
visit every
3/6 months†
visit every
3/6 months1
visit every
6 months
visit every
6 months
IIA visit every3 months
Visit every
3 months**
visit every
3/6 months†
visit every
3 months
visit every
4 months
visit every
3 months
IIB visit every3 months
visit every
3 months**
visit every
3 months†
visit every
3 months
visit every
4 months
visit every
3 months
IIC visit every3 months
visit every
3 months**
visit every
3 months†
visit every
3 months
visit every
4 months
visit every
3 months
* revised AJCC Classification.
** visit every 3 months for the first 3 years, then 6-monthly to 5 year.
1In consideration of Breslow thickness: for melanoma <1mm every 6 months; for melanoma >1 mm every 3 months.
† visit every 3 months for the first 2 years, then 6-monthly to 5 year.
Table 2. Clinical examination schedule (years 1-5 from diagnosis)
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Imaging examination schedule (years 1-5 from diagnosis)
Stage* Dummer, 2011 Marsden, 2010 Mangas, 2010 Garbe, 2009 Quaglino, 2008 Négrier, 2005
In situ Not required Not required Not required Not required Not required NA
IA
Regional
sonography every
6-12 months
No routine
investigation
required
Chest X-ray every 12
months; abdominal
sonography every 12
months (optional)
No routine
investigation
required**
Regional sonography
every 12 months
No routine
investigation
required
IB
Regional
sonography every
6-12 months
No routine
investigation
required
Chest X-ray every 6
months; abdominal
sonography every 6
months (optional)†
No routine
investigation
required**
Regional and abdomen
sonography every 12
months; chest X-ray
every 12 months
No routine
investigation
required
IIA
Regional
sonography every
6-12 months.
Abdominal
sonography and
chest X-ray
individually
No routine
investigation
required
Chest X-ray every 6
months; abdominal
sonography every 6
months (optional)†
No routine
investigation
required**
Regional and abdomen
sonography every 12
months; chest X-ray
every 12 months; TC scan
every 24 months
Regional
sonography every
3-6 months.
IIB
Regional
sonography every
6-12 months.
Abdominal
sonography and
chest X-ray
individually. CT scan
every 6-12 mo
No routine
investigation
required
CT scan every 6/12
months†
No routine
investigation
required**
Regional and abdomen
sonography every 12
months; chest X-ray
every 12 months; CT scan
every 12 months
Regional
sonography every
3-6 months.
IIC
Regional
sonography every 6
months. Abdominal
sonography and
chest X-ray
individually. CT scan
every 6-12 mo
No routine
investigation
required
CT scan every 6/12
months†
No routine
investigation
required
Regional and abdomen
sonography every 12
months; chest X-ray
every 12 months
Regional
sonography every
3-6 months.
PET-CT, and CT
scan individually
* revised AJCC Classification.
** sonography individually
† every 6 months for the first 3 years, then annually to 5 year
Table 3. Imaging examination schedule (years 1-5 from diagnosis)
2.5. Stage III melanoma
At the initial visit prior to surgical treatment, brain, chest, abdominal and pelvic CT is
recommended, in order to exclude visceral involvement; PET-CT and cranial MRI may be
Recent Advances in the Biology, Therapy and Management of Melanoma368
proposed as alternative; Catalan guidelines suggest also a bone scintigraphy as optional
(Mangas et al 2010).
Due to the high risk of visceral spreading in stage III patients, close follow-up and imag‐
ing investigations are accepted by almost all guidelines (Garbe et al 2010, Marseden et al
2010, Dummer et al 2010, Forschner et al 2010, Romano et al 2010). Head, chest and abdo‐
men CT scan is  normally useful  to detect  metastases,  with higher sensitivity than ultra‐
sound  imaging;  PET-CT  can  also  be  used  alternatively  (Negrier  et  al  2005).  However,
some other authors consider imaging investigation as optional in absence of specific sign
or symptoms (Coit et al 2009).
Literature data reports also a wide range of follow-up approaches, without precise rules for
timing and duration. A close follow-up regimen was proposed by Garbe et al (2003), with
clinical visits every 3 months for the first 5 year and then every 6 months up to 10 years after
lymph node dissection and instrumental examination (CT scan, PET-CT, chest x-ray or
abdominal and lymph nodal ultrasound) every 6 months. In the sample of patients examined,
a disease progression was detected by physical examination in almost the half of cases, and
by imaging in more than one third of cases; on the contrary, relapses were rarely early
discovered in patients outside of the scheduled follow-up. In this work, Garbe report a better
5-year survival in patients with early diagnosis of recurrences compared to that of patients
with unresectable metastases, supporting the validity of a close follow-up program (Garbe et
al 2003). Other similar follow-up programs (Hoffman et al 2002, Poo-Hwu 1999), with a
relatively high frequency of visits (3-monthly for almost 3 years), come to similar results. The
UK guidelines (Marsden et al 2010) suggest a 6-monthly follow-up to 5 years and then annually
to 10 years, whereas regular follow-up every 6 months with whole body imaging is recom‐
mended by others (Forschner et al 2010).
The study recently published by Romano et al. (2010), focused on stage III patients, evaluate
also the substage. For stage IIIA patients, the risk of loco-regional relapse was less than 5%
after 3 years from stage IIIA diagnosis, suggesting that beyond this point of time clinical
examinations may be referred. Similarly, the risk of loco-regional relapse dropped to less then
5% after 2 years from diagnosis for stage IIIB patients and after 7 months in stage IIIC. Stage
IIIC patients are the subset with higher risk of visceral spreading, with a 36% of patients that
develop the first relapse in the brain; so, this subgroup of patients should be subjected to
imaging examination more fequently
Even if routinely blood tests usually fail in the early detection of metastases, in stage III
melanoma patients tyrosinase (Osella- Abate et al 2003) or S100 (Dummer et al 2010, Forschner
et al 2010) has been demonstrated good marker for relapse.
2.6. Stage IV melanoma
No international follow-up guidelines are available for patients with metastatic disease. The
management strategy should be patient-taylored on the basis of primary melanoma charac‐
teristics, metastases site, age and general conditions.
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The development in the last few years of a novel class of targeted drugs (such as ipilimumab,
vemurafenib, imatinib) with an impact on survival, had an important effect on the manage‐
ment of these patients. C-kit and BRAF mutational state have to be evaluated in order to select
patients who can underwent this targeted therapies; also the identification of subgroups of
patients with different clinical behaviours is important for the right therapeutical choice,
especially for the drugs that need time to act (e.g anti-CTLA-4).
3. Conclusions
The main follow-up goal is the early detection of disease recurrence, which can allow a prompt
treatment with a potential prognostic benefit.
To date an international agreement about the most suitable follow-up guidelines for patients
who underwent a surgical excision of a primary melanoma is still lacking. Several national
guidelines are available, but the schedules differ as to the time frequency of both clinical visits
and imaging. However it is generally accepted that the frequency of clinical examinations must
to be decided on the basis of the AJCC stage at diagnosis and that a closer follow-up should
required in the first five years from diagnosis due to the higher risk of recurrence observed in
this time range. Regional node ultrasound is an useful tool for the detection of suspected
superficial adenopathies.
On the other hand, the role of imaging for the detection of visceral metastases in asymptomatic
patients is still a challenge: for low risk (IA) melanomas no routine investigations could be
required; sonography is generally used in follow up of intermediate/high risk melanoma
patients (IB to IIA), whereas the use of CT and PET scan is limited to patients with an higher
relapse risk (stage IIC or higher). It is generally accepted that the follow up's strategy for
disease-free stage III/IV patients, must to be tailored on the basis of clinical characteristics and
general conditions.
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